Childhood absence epilepsy (CAE) is considered to exhibit a complex non-mendelian pattern of inheritance. So far, only few CAE susceptibility genes have been identified. In a previous study of our group, an association between the GABA A receptor beta3 subunit (GABRB3) gene and CAE was shown. To further investigate this association we screened 45 CAE patients of the first study for mutations in the 10 exons, the exon/intron boundaries and the regulatory sequences of GABRB3.
INTRODUCTION
Accounting for 8 to 15% of all childhood epilepsies, childhood absence epilepsy (CAE) is one of the most frequently occurring syndromes among the idiopathic generalised epilepsies (IGEs). Its main clinical features are typical absence seizures associated with generalised 3Hz spike and wave discharges in the EEG (http://www.epilepsy.org/ctf/syn_frame.html). Evidence suggests that common forms of IGEs, including CAE, exhibit complex non-mendelian patterns of inheritance. Multiple genes seem to be simultaneously involved, and a diversity of susceptibility genes collaborate in determining risk with some contribution from environmental factors. (1) (2) (3) (4) . For CAE, so far only a few susceptibility genes have been identified, among them GABA A receptor genes (5, 6) .
GABA A receptors are chloride channels that can be opened by GABA and are the site of action of several antiepileptic drugs (7) (8) (9) . Any enhancement of the inhibitory actions of GABA A receptors causes anticonvulsive effects, whereas a reduction in the function of these receptors causes convulsions (7) . Congruently, three GABA A receptor subunit genes have been identified to be involved in the pathogenesis of inherited idiopathic epilepsies. Mutations in GABRG2, encoding the γ2-subunit were found in families with generalised epilepsy with febrile seizures plus (GEFS+) and CAE with febrile seizures (10) (11) (12) (13) . Mutations in GABRA1, encoding the α1-subunit, have been identified in a family with juvenile myoclonic epilepsy (14) and in a "sporadic" CAE-case (15) .
Coding variants in GABRD, encoding the δ-subunit seem also to be related to GEFS+ (16) .
An other major constituent of neuronal GABA A receptors is the β3 subunit. Whereas in adult brain it exhibits a relatively restricted pattern of expression, during development it is the most abundant and most widely expressed β-type subunit in the brain, indicating a potentially critical role of GABRB3 gene dosage in early brain development (17) (18) (19) .
In a previous study (20) , we were able to show an association between the GABA A receptor β3 subunit gene (GABRB3) and CAE in a group of patients with a high percentage of subjects suffering from absence seizures as the sole phenotype. Using the microsatellite DNA marker 155CA2 which is located within intron 3 of GABRB3 we demonstrated a significant association with CAE (p=0.0118) (20) . Significant differences were seen for the 107 bp allele of GABRB3, which was overrepresented in the patients and for the 95 bp allele of GABRB3, which was over-represented in the 4 control group. This association of the GABRB3 gene with CAE was replicated by another group (21) (22) (23) ) in a totally different population. Moreover, in eight families with remitting CAE a suggestive linkage of the GABRB3 gene was reported (24) , providing evidence for a significant impact of this locus in the development of CAE.
In the present study, we aimed to confirm the association of the GABRB3 gene and childhood absence epilepsy (20) and to identify the underlying genetic cause. Therefore, we performed a mutation screen in the GABRB3 gene to discover single nucleotide polymorphisms (SNPs). We then defined haplotypes for the GABRB3 gene region upstream of intron 3 for a subsequent association analysis. Finally, we examined the transcriptional activity of the GABRB3 gene exon 1a promoter haplotypes to investigate whether polymorphisms in this promoter region influence the GABRB3 gene expression. 
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RESULTS
Mutation screening and haplotype construction
The human GABRB3 gene has 10 exons (25) and contains two promoter regions upstream of the alternative first exons, exon 1a and exon 1 (26) (Fig. 1A) . Both alternative first exons are predicted to encode a signal peptide. Using PCR primers flanking each exon we screened the 5´-untranslated regions (5´-UTRs), the coding region and the 3´-UTR of the GABRB3 gene in 45 CAE patients by single strand conformation polymorphism (SSCP) analysis. To increase the efficiency of mutation detection for the longer exons 4, 7, 8 and 9, in these cases SSCP analyses were performed after restriction endonuclease digestion. Each candidate SNP was then confirmed by DNA sequencing. To search for SNPs in the promoter regions of the GABRB3 gene, we amplified and sequenced 1400 bp of the genomic DNA upstream of exon 1a and a 650 bp fragment between exon 1a and exon 1 in 11 patients and 9 unrelated control samples. As a result, a total of 13 SNPs were found, of which 2 SNPs were novel. The remaining 11 SNPs had already been deposited in the dbSNP database (http://www.ncbi.nlm.nih.gov/SNP/index.html). From the 13 SNPs eight were located in the promoter region upstream of exon 1a, two SNPs in exon 1a, two SNPs in the promoter region upstream of exon 1, and one SNP in intron 3 just 13 basepairs downstream of the exon (see table 1 and Fig. 1A ).
As the mutation screening of the coding exons 4 to 10 of GABRB3 did not identify any functionally relevant mutation or SNP, we considered that genetic alterations underlying the observed association are located in the region upstream of marker 155CA2 containing both promoter regions and the exons 1a, 1, 2, and 3. To improve coverage of the 12 kb GABRB3 gene region between the exon 1a promoter and the associated microsatellite marker 155CA2 that is situated at the very beginning of the 150 kb long intron 3, we selected one additional intron 3 marker (rs3212333) from the dbSNP database (http://www.ncbi.nlm.nih.gov/SNP/index.html). In order to construct haplotypes, the genotypes derived by direct sequencing of the promoter regions in the 11 patients and 9 unrelated control samples were combined with the genotypes of the SNPs generated by PCR-RFLP in the same 20 individuals. Based on these genotypes we were able to define 4 haplotypes for the GABRB3 gene region ranging from the promoter upstream of exon 1a to the beginning of intron 3. By inspection of 6 the data we recognised that a combination of 6 haplotype tagging SNPs (htSNPs) is sufficient to capture the full haplotype information in this region of interest (table 2) .
Association analysis
In the present study, 45 from the previously investigated 50 CAE trios (20) 
Functional analysis of the GABRB3 gene promoter haplotypes
Due to the fact that mutation screening of the exons and exon/intron boundaries of the GABRB3 gene upstream of intron 3 did not identify any functionally relevant nucleotide exchanges, we proposed that sequence variations located in the promoter region could be the basis for this significant association between GABRB3 gene haplotypes and CAE. To test this hypothesis, in vitro luciferase reporter gene assays were performed. For that, we subcloned different haplotypes of GABRB3 exon 1a promoter sequences (nucleotides -979 to -4, numbering with respect to the initiator methionine of exon 1a) into the promoterless luciferase reporter plasmid pGL3-Enhancer. These promoter constructs were 7 transiently transfected in parallel into a human neuronal-like cell line (NT2) and into non neuronal HEK293 cells, in order to compare their ability to drive luciferase gene expression as a measure for their transcriptional activities. The relative levels of luciferase expression with these constructs are shown in Fig. 1B . In NT2 cells, as hypothesised, haplotype 2 promoter constructs conferred significantly lower transcriptional activity than haplotype 1 promoter constructs. In HEK293 cells, none of the exon 1a promoter constructs exhibited promoter activity, since their activity did not exceed the activity of the promoter-less control plasmid pGL3-enhancer transfected in parallel (data not shown).
Bioinformatic analysis of the GABRB3 exon 1a promoter haplotypes
To assess the functional importance of sequence variations in the GABRB3 exon 1a promoter region, we performed a sequence analysis of the exon 1a promoter SNP regions. We identified two SNPs that 
Determination of altered nuclear protein binding by electrophoretic mobility shift assay (EMSA)
To investigate a possible reduced binding of transcription factors, electrophoretic mobility shift assays were performed in order to determine whether DNA-protein interaction occurs in the GABRB3 exon formation of three complexes is in good agreement with previous reports (27, 28) describing that during nuclear extract preparation, in vitro proteolysis generates two additional proteins which can also bind to the N-Oct-3 sequence motif. Thus, binding of intact N-Oct-3 should correspond to the DNA-protein complex C1, whereas C2 and C3 should represent the DNA-protein complexes of the two degradation products. Unfortunately, no N-Oct-3 antibody currently is available that could be used for supershift assays to confirm the identity of these three complexes.
The formation of these complexes was partially inhibited by increasing amounts of the competing unlabelled -897 T probe (lanes 3-5) or -897 C probe (lanes 6-8). Interestingly, comparison of lanes 3-5 with lanes 6-8 indicated differences in the effectiveness of the two alleles as competitors for protein binding. Thus, when complexes C1, C2, and C3 were compared in lanes 3 and 6, labelling was 30%, 80% and 35% higher in lane 6, respectively, than in lane 3. Similar results were obtained when lanes 4 and 7, or lanes 5 and 8 were compared. These data indicated that the -897 T to C alteration may indeed reduce nuclear protein binding affinity.
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DISCUSSION
Based on the results of a previous association study (20) , we performed a mutation screen in the GABRB3 gene of these patients to detect genetic alterations that could contribute to the development of childhood absence epilepsy. We did not find amino acid exchanges in the coding regions or polymorphisms in the potential exon/intron splice sites that could play a role in the pathogenesis of CAE in our patient group. Therefore we assumed that the disease causing genetic variations may be located in the GABRB3 gene regulatory regions. We defined 4 haplotypes for the region upstream of the previously associated microsatellite marker 155CA2 for a subsequent association analysis. Results indicated that haplotype 2 of GABRB3 is associated with CAE. Since haplotype 2 shares either the thought that exon 1a regulation is important for early neuronal development. Consequently, the effects of GABRB3 gene mutations might appear in a limited time frame, and the genes might be switched on or off as a function of age, controlling the predisposition, expression, modulation, and temporal sequence of childhood-onset idiopathic generalised epilepsies. Congruently, childhood absence epilepsy is characterised by an age-dependent onset, and in the majority of the CAE patients absences disappear with age (31, 32) .
Direct evidence that a reduction of GABRB3 expression can result in epilepsy is provided by the characteristics of the gabrb3 gene knockout mice. These mice exhibit a high incidence of neonatal mortality, cleft palate, seizures as well as EEG abnormalities, often associated with arrested behaviour resembling an absence seizure (33). Moreover, our results correspond with the concept of the pathophysiological mechanisms of absence seizures studied in various animal models with generalised spike and wave discharges associated with behavioral arrest (34-37). It appears that generalised spike and wave discharges are generated and sustained by highly synchronised abnormal oscillatory rhythms in thalamocortical networks that mainly involve neocortical pyramidal cells, the reticular thalamic nucleus, and the relay nuclei of the thalamus (36) . In case of a reduced GABRB3 expression level, the number of GABA A receptors in the thalamic reticular neurons also is reduced, as the β3 subunit is the most abundant GABA A receptor subunit in early development (18) . A reduced GABAergic inhibition between the thalamic reticular neurons leads to an increase of their pacemaking capacity and therefore to an increased likelihood of generating absence seizures. This concept corresponds to the observed increased hypersynchrony of thalamic network activity in gabrb3 knockout mice (38) . 
MATERIALS AND METHODS
Subjects and Diagnosis
Subjects investigated in this study were taken from the previously studied CAE trios (20) recruited by the outpatient division for seizure disorders at the Department of Child and Adolescent Neuropsychiatry, Medical University of Vienna. Diagnosis of CAE, inclusion/exclusion criteria and pre-entry confirmatory examinations have been already described (20) . Patients and/or their parents had to provide informed written consent. The study was performed according to a protocol approved by the local Ethical Committee.
DNA isolation and SSCP analysis
High molecular weight genomic DNA was extracted from each blood sample using the Nucleon BACC3 kit (Amersham Biosciences). DNA from 45 CAE patients was used to screen for polymorphisms in the GABRB3 gene by single strand conformation polymorphism (SSCP) analysis.
Fragments containing the GABRB3 exons including all exon-intron boundaries were amplified by PCR. The oligonucleotide primers and the PCR conditions used have been published (25) . Briefly, 100 ng of genomic DNA was amplified using 5 pmol each of the forward and reverse exon primer, 2.0 mM dNTPs, 1x PCR buffer (QIAGEN) and 0.5 units QIAGEN Taq DNA polymerase in a final volume of 25 µl. 4 µl of formamide solution (95% formamide, 20 mM EDTA, 10 mM NaOH, 0.02% bromophenol blue, 0.02% xylene cyanol) was added to 4 µl of PCR product. After denaturation for 5 min at 95°C and cooling on ice, each sample was loaded immediately on a CleanGel 48S (Amersham Biosciences) equilibrated with the rehydratation buffer. Electrophoresis was performed using the Multiphor II Electrophoresis Unit (Amersham Biosciences). Gels were subsequently silver stained with PlusOne Silver Staining Kit (Amersham Biosciences) and analysed for possible band shifts. A modification of SSCP, called restriction fragment fingerprinting was used for longer amplicons (300 -600 bp). For that, the PCR fragments were digested with restriction endonucleases, denatured and then scanned for mutations by non-denaturing gel electrophoresis as described above. 
Sequencing analysis
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The results of SSCP analysis were confirmed by sequencing both strands of the DNA fragments with different ssDNA-mobility-patterns (custom sequencing performed by VBC-BIOTECH Services GmbH, Vienna).
SNP genotyping
The diallelic haplotype-tagging SNPs listed in table 1 were all typed by polymerase chain-reaction restriction fragment length polymorphism (PCR-RFLP) analysis. PCR primers flanking the polymorphisms were designed by using the Primer3 program (http://frodo.wi.mit.edu/cgibin/primer3/primer3_www.cgi). All SNPs were amplified by the same procedure. Briefly, 100 ng of genomic DNA was amplified using 5 pmol each of the forward and reverse primer (see supplementary Material, Table S1 ), 2.0 mM dNTPs, 1x PCR buffer with or without Q-solution (QIAGEN) and 0.5 units QIAGEN Taq DNA polymerase in a final volume of 25 µl. Cycling conditions were 95°C for 2 min, followed by 35 cycles of 94°C for 30 s, annealing at the appropriate temperature for 30 s, and synthesis at 72°C for 30 s, and finally, a 2 min extension at 72°C. PCR products were digested with the appropriate restriction enzyme (table 1) , according to the manufacturer´s protocol. Digested products were run on agarose gels, stained with ethidium bromide, and scored by UV visualisation.
Reporter plasmid construction
Recombinant plasmids for reporter gene assays were constructed by cloning DNA fragments from the exon 1a promoter region of the GABRB3 gene representing haplotype 1 and haplotype 2, respectively, into the reporter vector pGL3 Enhancer (Promega, Mannheim, Germany), which contains an SV40 enhancer located downstream of the luciferase gene but lacks upstream eukaryotic promoter. The enhancer containing reporter vector was chosen to facilitate the detection of weak promoters. The exon 1a promoter region, a 976 bp fragment spanning from -979 to -4 (numbering with respect to the initiator methionine of exon 1a; GenBank accession no. NT_026446) was PCR amplified from genomic DNA of probands that were homozygous for either haplotype 1 or haplotype 2 using genespecific primers containing either a Sac I (forward primer) or a Bgl II (reverse primer) restriction site at their 5´-end. PCR was performed using AccuPrime GC-rich DNA polymerase (Invitrogen) calf serum, 2 mM glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin at 37°C in an atmosphere of 5% CO 2 by using standard cell culture techniques as described previously (44) . Cells were plated at a density of 1.5 -2. Aliquots of the lysates were assayed for luciferase activity using the Bright-Glo TM Luciferase Assay System (Promega). A promoterless pGL3 enhancer-vector defined the base line for promoter activity, while a pGL3 luciferase gene construct with SV40 promoter and enhancer (pGL3 control, Promega, Mannheim, Germany) served as a positive control for luciferase expression and a monitor for transfection efficiency in every experiment. Initial experiments used co-transfection with an SV40-β-galactosidase reporter vector for normalisation of the data. This approach was abandoned because of strong interaction between the two promoter constructs (substantial luciferase activity determined in single transfections was dramatically reduced in co-transfections), as reported in other systems (47) .
All transfections were performed in triplicate; each experiment was repeated at least six times. In order to exclude that differences in the purity of the various plasmid constructs could affect luciferase expression, experiments were performed with different plasmid preparations.
Preparation of nuclear cell extracts
Nuclear extracts from NT2 cells were prepared from 90% confluent cultures in 100 mm 2 dishes. All extraction procedures were performed on ice with ice-cold reagents. Cells were washed twice with 2 ml of PBS and lysed by addition of 0.5 ml of hypoosmotic buffer (10 mM HEPES-KOH, pH 7.9; 10 mM KCl, 1.5 mM MgCl 2 , 1 mM DTT, 0.4% Nonidet P-40, 1 tablet Complete™ Mini EDTA free protease inhibitor (Roche) was added before use per 10 ml solution) directly to the plate. After an incubation of 10 min at room temperature the lysates were scraped from the plates and centrifuged at 4°C, 15 000 xg for 3 min. The pelleted nuclei from one plate were resuspended in 150 µl of high-salt buffer (20 mM HEPES-KOH, pH 7.9; 420 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 25% glycerol, 1 mM DTT and 1 tablet Complete™ Mini EDTA free protease inhibitor, Roche, was added before use per 10 ml solution) to solubilise the DNA-binding proteins. The suspended nuclei were vigorously shaken for 90 min at 4°C and centrifuged (20 min, 15 000 xg, 4°C). The clear supernatants containing the nuclear proteins were stored in small aliquots at -80°C until used for EMSA. Protein concentration was determined using the BCA Protein Assay system (Pierce, Rockford, IL, USA) as described above.
Electrophoretic mobility shift assay (EMSA)
Complementary oligonucleotides to detect the -897 SNP were synthesized by VBC-BIOTECH Service GmbH, Vienna (forward 5´-TATATTTAAAATTAATGCACAG-3´ and reverse 5´-CTGTGCATTAATTTTAAATATA-3´ for the -897 T variant, and forward 5´-TATATTTAAAATCAATGCACAG-3´ and reverse 5´-CTGTGCATTGATTTTAAATATA-3´ for the -897 C variant). The two -897 variant-specific double-stranded oligonucleotides were generated by heating the complementary oligonucleotides in a buffer solution (10 mM Tris-HCl, pH 7.5, 20 mM NaCl) at 95°C for 5 min, and then allowed to cool to room temperature. For EMSA, oligonucleotide probes were end-labelled with [γ-33 P] ATP (3000 Ci/mmol, Hartmann Analytic, Germany) using T 4 polynucleotide kinase (Promega) and purified on MicroSpin G-25 columns (Amersham Biosciences).
Unlabelled double-stranded oligonucleotides were used as sequence-specific competitors. Consensus AP2 oligonucleotide (Promega) was also used as a non specific competitor. Binding was performed in a 10 µl reaction mixture by using the Gel Shift Assay Systems (Promega). 5 µg of nuclear proteins 
Statistics
For association analysis, a nuclear family-based candidate gene approach was applied. In families ascertained for the presence of an affected child, the genotype of the affected offsprings (made up of the transmitted parental haplotypes) was used as the case sample, and an artificial genotype derived from the non transmitted parental haplotypes formed the affected family-based control sample. This matched design for patient (parental transmitted) and control (parental non transmitted) marker alleles avoids ethic confounding in the case of a stratified population (48 and that of the free probe are indicated by arrows. 
